Pharma: Other News To Note
Thursday, April 25, 2013
GE Healthcare, of Chalfont St. Giles, UK, and Eisai Inc., of Woodcliff Lake, N.J., inked a research collaboration agreement for use of the GE Healthcare investigational PET amyloid imaging agent flutemetamol to help select patients for a Phase I trial testing Eisai's E2609, a BACE inhibitor for the potential treatment of Alzheimer's disease.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.